The Zentiva group was established in 2003 ( Former companies were Slovakofarma and Léčiva) as Zentiva B.V. which one year later changed its name to Zentiva N.V. It is an international pharmaceutical company that develops, manufactures and markets modern branded generic pharmaceutical products as well as OTC, cosmetic products and pharmaceutical substances. Company's core markets are; Czech Republic, Romania, Poland, Slovakia, and Russia. Zentiva addresses a wide range of therapeutic areas but has particular focus on cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system, as well as the gastrointestinal and urology fields. In June 2004 Zentiva listed its shares on the Prague and London Stock Exchanges. In 2005 Zentiva acquired Venoma Holding which hold %51 of Sicomed and later with the additional acquisitions of shares it now owns 74.9% of Sicomed which has changed its name to Zentiva S.A. In 2006 Sanofi-Aventis acquired the 24.9% of the company . In 2007 Company acquired 75% stake in Eczacýbașý Generic Pharmaceuticals.

Company was acquired by Sanofi

Acquired Companies: Sicomed, Zentiva, A.S. Praha, Zentiva, a.s. Hlohovec